الفهرس 
Influenza virusOnly 14 pages are availabe for public view
 |  | from | 152 |  |  |
| | | from | 152 | | |
Abstract
The challenges in successful vaccination against influenza using
conventional approaches lie in their variable efficacy in different age
populations, the antigenic variability of the circulating virus, the production
and the manufacturing limitations to insure safe, timely, and adequate supply
of vaccine. The conventional influenza vaccine platform is based on
stimulating immunity against the major neutralizing antibody target,
hemagglutnin (HA), by virus attenuation or inactivation. Improvements to this
conventional system have focused essentially on improving the production and
immunogenicity. Cell culture, reverse genetics, and baculovirus expression
technology allow for safe production, while adjuvants, dose alternate delivery
routes and variations, which could target the vaccine immunogenicity
improvements. Influenza virus-like particle (VLPs), viral antigens lack nucleic
acids which are non-infectious, limit the risk of recombination with wild-type
strains. This study focused on producing an Egyptian Avian influenza VLP
isolate (A/Turkey/Egypt/7/2007 (H5N1)) generated by using baculovirus
expression system into SF9 cells, where the HA & M1 genes were sub-cloned
into TA cloning vector; farther cloned into pAcAB4 Baculovirus Transfer
Vector. The generated influenza VLPs were observed photographed by
transmitted electron microscope (TEM) and detected by measuring HA activity
(22 HAU/25μl), hemadsorbtion activit, SDS-PAGE, and Western blot. This
study discuss the preliminary creation of identified Egyptian isolate influenza
VLPs vaccine in Baculovirus expression& insect cell system which could be in
large scale is more rapid and easy than other production technologies. It is
essential that further immune response studies on the Egyptian isolate
generated Influenza VLPs to be carried out.